Skip to content
‹ Back to IndustriesHealthcare

President Biden’s National Drug Control Strategy

The opioid crisis in the United States is on the rise. Overdose deaths continue to escalate, even with increased measures to curtail illegal access to subscription medication. The CDC estimates annual overdose deaths top 100,000.  On April 21, 2022, President Biden provided Congress with his administration’s first National Drug Control Strategy. The strategy focuses on…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The opioid crisis in the United States is on the rise. Overdose deaths continue to escalate, even with increased measures to curtail illegal access to subscription medication. The CDC estimates annual overdose deaths top 100,000. On April 21, 2022, President Biden provided Congress with his administration’s first National Drug Control Strategy. The strategy focuses on two drivers of the epidemic: untreated addiction and drug trafficking.

 
Eliminating Illegal Drugs Does Not Eliminate Addiction

The President’s Drug Control Strategy proposes several methods for reducing domestic and international drug production and trafficking, including increased border protection and $300 million in the Drug Enforcement Administration’s budget. How much of an impact will these efforts make? It is impossible to determine at present, but Dr. Michael Sprintz, Founder and CEO of the Sprintz Center for Pain, pointed out that even if the United States could eliminate all illegal drugs coming across its borders, drug addiction would not simply go away.

“Eliminating the supply does not change the demand,” said Dr. Michael Sprintz. “We saw this play out as the DEA decreased the availability of prescription opioids, and yet what happened was the demand for opioids from people with addictive disease didn’t decrease.”

Harm reduction efforts are another important component in the fight against addiction, as the availability of fentanyl and other synthetic drugs make overdoses more common and more deadly. In 2020, the U.S. attributed 56,516 overdose deaths to synthetic opioids (primarily fentanyl.) Increasing the availability of life-saving drugs like NARCAN® and safe needle-exchange programs will help save lives. Still, harm reduction efforts do not solve the core problem, which is treating the addiction and getting patients the care they need to recover.

 
It’s Not Just About Getting Access to Care

Increasing access to care is a welcomed part of the Biden plan, but care, in and of itself, is not a total solution. “It’s about having access to evidence-based, affordable care,” Dr. Sprintz said. “You can have access to care to get treatment for a substance abuse problem, but if you can’t afford it, it doesn’t matter that you have access to it.”

Affordable, available, and successful treatment services are paramount to stopping addiction in this country. “If we don’t have treatment services to help people not just get sober, but stay sober, to give them the tools to help them cope with life on life’s terms, then we’re screwed,” Dr. Sprintz said.

The efforts to make more affordable treatment services available to people suffering from addiction is what Dr. Sprintz believes is the most important takeaway from the Biden drug control strategy. “We need to give access to care to as many people as we can and do it in a way that we can afford it.”

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Healthcare AI should give doctors attention back, not shorter visits

Healthcare AI should give doctors attention back, not shorter visits

Healthcare organizations should deploy AI to give clinicians back attention and capacity for better decisions, not simply shorten visits. Landry argues AI should fit into existing workflows with insights appearing at the right time, and that organizations should set clear governance and automation boundaries before deployment and measure what changes for patients, clinicians and the organization.

  • 01AI success in healthcare should expand clinician capacity for thoughtful care, not optimize for visit speed; a three-minute appointment is not patient-centered innovation.
  • 02Design AI into workflows clinicians already use with insights appearing at the right moment, making adoption a workflow problem rather than a training problem.
  • 03Set automation boundaries before deploying AI, specifying what it may do alone, what it recommends for clinician decision-making, and what requires explicit human control and accountability.

Nov 11, 2026

Black Book: AI may make some outsourced health plan work cheaper to bring in-house

Black Book: AI may make some outsourced health plan work cheaper to bring in-house

U.S. health plan administrative costs rose 2.7% to about $69.2 billion in the first half of 2026, even as margins improved to 4.1%. Black Book Research's 2027 outlook says AI is starting to move payer sourcing in both directions. Demand for specialist vendors stays strong in some functions, while automation could make in-house or hybrid models viable in others. The report recommends comparing each major outsourced service with rival vendors and the best internal or hybrid option, and checking whether projected savings become actual cash.

  • 01Every major outsourced payer service should be benchmarked against a rival vendor and against the plan's best feasible internal or hybrid model, a three-way contest at each renewal.
  • 02Avoided vacancies, projected productivity gains and payment recoveries are not recurring cash, so outsourcing savings should not be assumed to fund AI until the service, AI and funding cases each stand on their own.
  • 03Provider data sits on both sides of the sourcing question: it is a top pain point and a specialist-demand area, yet also one of the functions where automation could make hybrid or in-house models viable.

Nov 11, 2026

Hugh Chatham surgical tech program draws 65 for 12 seats

Hugh Chatham surgical tech program draws 65 for 12 seats

Hugh Chatham Health and Alleghany Health marked one year with Advocate Health as a surgical technology program drew 65 applicants for 12 seats. An anniversary release lists $11.3 million in pay and rewards and a $19.3 million capital figure, and says nearly 1,000 patients were connected to specialty and higher-acuity services through Atrium Health Wake Forest Baptist. Local training seats look like the next limit in Elkin.

  • 01In rural North Carolina, a new surgical technology program drew more than five applicants per seat, which points to training capacity, not interest, as the thing to expand.
  • 02Pay and rewards totaled $11.3 million in year one, versus a $19.3 million capital figure—about 58% as large, by MarketScale’s arithmetic.
  • 03Nearly 1,000 patients were connected to specialty and higher-acuity services versus just over 70 virtual consultations and encounters (about 14:1 by MarketScale’s arithmetic), with expanded virtual care planned for year two.

Nov 10, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512